PELI3

Summary

PELI3 (pellino E3 ubiquitin protein ligase family member 3, HGNC:30010) is a protein-coding gene on chromosome 11q13.2, encoding E3 ubiquitin-protein ligase pellino homolog 3 (Q8N2H9). E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins.

The protein encoded by this gene is a scaffold protein and an intermediate signaling protein in the innate immune response pathway. The encoded protein helps transmit the immune response signal from Toll-like receptors to IRAK1/TRAF6 complexes. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 246330 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_145065

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30010
Approved symbol	PELI3
Name	pellino E3 ubiquitin protein ligase family member 3
Location	11q13.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC35521
Ensembl gene	ENSG00000174516
Ensembl biotype	protein_coding
OMIM	609827
Entrez	246330

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 17 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000320740, ENST00000349459, ENST00000524466, ENST00000526296, ENST00000527230, ENST00000528752, ENST00000531856, ENST00000532970, ENST00000618547, ENST00000904606, ENST00000904607, ENST00000904608, ENST00000904609, ENST00000939615, ENST00000972025, ENST00000972026, ENST00000972027, ENST00000972028, ENST00000972029

RefSeq mRNA: 4 — MANE Select: NM_145065 NM_001098510, NM_001243135, NM_001243136, NM_145065

CCDS: CCDS31615, CCDS41675, CCDS73328

Canonical transcript exons

ENST00000320740 — 8 exons

Exon	Start	End
ENSE00001188900	66468833	66468904
ENSE00001188939	66472369	66472470
ENSE00001188948	66468128	66468280
ENSE00001363502	66466905	66467027
ENSE00002201832	66475598	66477337
ENSE00003495576	66471242	66471371
ENSE00003587961	66473737	66473925
ENSE00003629756	66473241	66473435

Expression profiles

Bgee: expression breadth ubiquitous, 245 present calls, max score 96.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.0464 / max 68.3234, expressed in 1674 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115342	6.0464	1674

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	96.35	gold quality
endothelial cell	CL:0000115	95.73	silver quality
middle temporal gyrus	UBERON:0002771	95.38	gold quality
primary visual cortex	UBERON:0002436	93.32	gold quality
substantia nigra pars reticulata	UBERON:0001966	93.17	gold quality
pons	UBERON:0000988	92.92	gold quality
occipital lobe	UBERON:0002021	92.90	gold quality
lateral nuclear group of thalamus	UBERON:0002736	92.56	gold quality
cerebellar vermis	UBERON:0004720	92.15	gold quality
prefrontal cortex	UBERON:0000451	91.84	gold quality
substantia nigra pars compacta	UBERON:0001965	91.72	gold quality
medial globus pallidus	UBERON:0002477	91.28	gold quality
right frontal lobe	UBERON:0002810	91.27	gold quality
frontal cortex	UBERON:0001870	91.11	gold quality
superior vestibular nucleus	UBERON:0007227	90.98	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.69	gold quality
globus pallidus	UBERON:0001875	90.63	gold quality
tendon of biceps brachii	UBERON:0008188	90.30	gold quality
neocortex	UBERON:0001950	90.24	gold quality
superior frontal gyrus	UBERON:0002661	90.02	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	89.99	gold quality
ventral tegmental area	UBERON:0002691	89.68	gold quality
medulla oblongata	UBERON:0001896	89.67	gold quality
parietal lobe	UBERON:0001872	89.61	gold quality
cerebral cortex	UBERON:0000956	89.33	gold quality
lateral globus pallidus	UBERON:0002476	89.29	gold quality
kidney epithelium	UBERON:0004819	88.94	gold quality
anterior cingulate cortex	UBERON:0009835	88.89	gold quality
postcentral gyrus	UBERON:0002581	88.81	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

48 targeting PELI3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-548Q	98.71	65.35	563
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-4469	97.93	65.81	1319
HSA-MIR-3144-5P	97.64	65.45	646
HSA-MIR-4308	97.56	67.13	1385
HSA-MIR-3127-5P	97.52	65.24	786

Literature-anchored findings (GeneRIF, showing 11)

• Pellino3 is a novel upstream regulator of p38 MAPK that activates CREB in a p38-dependent manner (PMID:15917247)
• suggest that Pellino 3b acts as a negative regulator for IL-1 signaling by regulating IRAK degradation through its ubiquitin protein ligase activity [Pellino 3b] (PMID:18326498)
• Our findings identify RIP2 as a substrate for Pellino3 and Pellino3 as an important mediator in the Nod2 pathway and regulator of intestinal inflammation. (PMID:23892723)
• Peptide PEL3 derived from the interleukin-1 receptor-associated kinase (IRAK)1-binding motif reveals a distinct phosphothreonine peptide binding preference. (PMID:25027698)
• Pellino-3 is involved in endotoxin tolerance and functions as a negative regulator of Toll-like receptor 2/4 signaling. (PMID:26310831)
• The combination of low Pellino3 levels together with high and inducible Pellino1 expression may be an important determinant of the degree of inflammation triggered upon Toll-like receptor 2 engagement by Helicobacter pylori and/or its components, contributing to Helicobacter pylori-associated pathogenesis by directing the incoming signal toward an NF-kB-mediated proinflammatory response. (PMID:27302665)
• Two protective, low-frequency, non-synonymous variants were significantly associated with a decrease in age-related macular degeneration (AMD)risk: A307V in PELI3 and N1050Y in CFH .We also identified a strong protective signal for a common variant (rs8056814) near CTRB1 associated with a decrease in AMD risk (logistic regression: OR = 0.71, P = 1.8 x 10-07). (PMID:28011711)
• PELI3 gene expression in blood and ovarian cancer. (PMID:31520466)
• Long Non-coding RNA MIAT Mediates Non-small Cell Lung Cancer Development Through Regulating the miR-128-3p/PELI3 Axis. (PMID:32556677)
• miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3. (PMID:32635799)
• Pellino3 ligase negatively regulates influenza B dependent RIG-I signalling through downregulation of TRAF3-mediated induction of the transcription factor IRF3 and IFNbeta production. (PMID:36861386)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	peli3	ENSDARG00000087452
mus_musculus	Peli3	ENSMUSG00000024901
rattus_norvegicus	Peli3	ENSRNOG00000019950
drosophila_melanogaster	Pli	FBGN0025574
caenorhabditis_elegans		WBGENE00017766

Paralogs (2): PELI2 (ENSG00000139946), PELI1 (ENSG00000197329)

Protein

Protein identifiers

E3 ubiquitin-protein ligase pellino homolog 3 — Q8N2H9 (reviewed: Q8N2H9)

All UniProt accessions (5): Q8N2H9, E9PI91, E9PQX6, E9PR85, H0YEM6

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates ‘Lys-63’-linked polyubiquitination of IRAK1. Can activate AP1/JUN and ELK1. Acts as a regulator of innate immunity by mediating ‘Lys-63’-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling. Catalyzes ‘Lys-63’-linked polyubiquitination of RIPK2 in parallel of XIAP.

Subunit / interactions. Interacts with TRAF6, MAP3K14 and MAP3K7.

Tissue specificity. Highly expressed in brain, heart and testis, and at lower level in kidney, liver, lung, placenta, small intestine, spleen and stomach. Isoform 1 is not expressed in lung.

Post-translational modifications. Phosphorylated by IRAK1 enhancing its E3 ligase activity.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the pellino family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8N2H9-1	1, Alpha, A	yes
Q8N2H9-2	2, Beta, B
Q8N2H9-3	3
Q8N2H9-4	4

RefSeq proteins (4): NP_001091980, NP_001230064, NP_001230065, NP_659502* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006800	Pellino_fam	Family
IPR048334	Pellino_FHA	Domain
IPR048335	Pellino_RING	Domain

Pfam: PF04710, PF20723

UniProt features (10 total): splice variant 4, sequence conflict 2, chain 1, region of interest 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N2H9-F1	81.91	0.59

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 11

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9020702	Interleukin-1 signaling
R-HSA-937039	IRAK1 recruits IKK complex
R-HSA-975144	IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation

MSigDB gene sets: 80 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, CAGGTCC_MIR492, CACCAGC_MIR138, chr11q13, GOBP_NEGATIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_APOPTOTIC_SIGNALING_PATHWAY, GOBP_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, E4F1_Q6, GOBP_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

GO Biological Process (8): regulation of Toll signaling pathway (GO:0008592), negative regulation of tumor necrosis factor-mediated signaling pathway (GO:0010804), innate immune response (GO:0045087), protein K63-linked ubiquitination (GO:0070534), negative regulation of extrinsic apoptotic signaling pathway (GO:2001237), protein polyubiquitination (GO:0000209), immune system process (GO:0002376), protein ubiquitination (GO:0016567)

GO Molecular Function (3): ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Interleukin-1 family signaling	1
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	1
MyD88 cascade initiated on plasma membrane	1
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
Toll signaling pathway	1
regulation of signal transduction	1
negative regulation of cytokine-mediated signaling pathway	1
regulation of tumor necrosis factor-mediated signaling pathway	1
tumor necrosis factor-mediated signaling pathway	1
immune response	1
defense response to symbiont	1
protein polyubiquitination	1
extrinsic apoptotic signaling pathway	1
negative regulation of apoptotic signaling pathway	1
regulation of extrinsic apoptotic signaling pathway	1
protein ubiquitination	1
biological_process	1
protein modification by small protein conjugation	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

674 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PELI3	IRAK1	P51617	971
PELI3	TRAF6	Q9Y4K3	832
PELI3	IRAK4	Q9NWZ3	749
PELI3	TAB1	Q15750	665
PELI3	TLR4	O00206	600
PELI3	RIPK2	O43353	599
PELI3	MAP3K7	O43318	595
PELI3	TOLLIP	Q9H0E2	586
PELI3	MYD88	P78397	586
PELI3	MAPKAPK2	P49137	569
PELI3	MAP3K14	Q99558	545
PELI3	IL1R1	P14778	540
PELI3	SMAD6	O43541	529
PELI3	TAB2	Q9NYJ8	507
PELI3	ECSIT	Q9BQ95	490

IntAct

10 interactions, top by confidence:

A	B	Type	Score
PIK3R3	PELI3	psi-mi:“MI:0915”(physical association)	0.570
PELI3	PRKACG	psi-mi:“MI:0915”(physical association)	0.400
PELI3	TRAF6	psi-mi:“MI:0915”(physical association)	0.400
PELI3	IRAK1	psi-mi:“MI:0915”(physical association)	0.400
CAMK2G	PSMD12	psi-mi:“MI:0914”(association)	0.350
PELI3	ZNF195	psi-mi:“MI:0914”(association)	0.350
ADORA1	SORBS3	psi-mi:“MI:0914”(association)	0.350

BioGRID (78): IRAK1 (Affinity Capture-Western), UQCRFS1 (Affinity Capture-Western), TRAF6 (Affinity Capture-Western), KANK2 (Affinity Capture-MS), STUB1 (Affinity Capture-MS), DNAJB4 (Affinity Capture-MS), PELI3 (Two-hybrid), PIK3R3 (Affinity Capture-Luminescence), PELI3 (Synthetic Lethality), PELI3 (Two-hybrid), PELI3 (Two-hybrid), PELI3 (Affinity Capture-RNA), PRKACG (Affinity Capture-MS), PELI3 (Affinity Capture-MS), TUBA1A (Affinity Capture-MS)

ESM2 similar proteins: A2VE39, A2X0Q3, D2HRF1, D3ZVK1, E1BMF7, I0IUP3, O42130, O42131, O46374, O76808, O77237, P11388, P24785, P41515, P41516, Q01320, Q02880, Q10322, Q1MTD3, Q24498, Q298L5, Q3SZ41, Q4VSI4, Q5R981, Q5RFK6, Q5U2Z5, Q64399, Q64511, Q6A4J8, Q6ESI7, Q6GQ76, Q6NUA1, Q6NUH3, Q6YXZ7, Q6Z9U7, Q803R5, Q8AVL0, Q8BXR6, Q8IMX7, Q8K224

Diamond homologs: O77237, Q8BST6, Q8BXR6, Q8C669, Q8N2H9, Q96FA3, Q9HAT8

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
IRAK1	up-regulates	PELI3	phosphorylation
PELI3	up-regulates	ELK1
PELI3	up-regulates	JUN
PELI3	up-regulates	IRAK1	ubiquitination
PELI3	“down-regulates quantity”	TRAF6	ubiquitination
PELI3	“up-regulates activity”	RIPK2	ubiquitination
PELI3	“down-regulates activity”	IRF4	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	28
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1224 predictions. Top by Δscore:

Variant	Effect	Δscore
11:66468121:T:TA	acceptor_gain	1.0000
11:66468126:AGAAT:A	acceptor_gain	1.0000
11:66468127:GAATG:G	acceptor_gain	1.0000
11:66471207:T:A	acceptor_gain	1.0000
11:66471210:A:AG	acceptor_gain	1.0000
11:66471211:A:G	acceptor_gain	1.0000
11:66471224:A:AG	acceptor_gain	1.0000
11:66471225:A:G	acceptor_gain	1.0000
11:66471234:A:AG	acceptor_gain	1.0000
11:66471237:TACA:T	acceptor_loss	1.0000
11:66471238:ACAG:A	acceptor_loss	1.0000
11:66471239:C:G	acceptor_gain	1.0000
11:66471239:CAGCT:C	acceptor_loss	1.0000
11:66471240:A:AG	acceptor_gain	1.0000
11:66471241:G:GT	acceptor_gain	1.0000
11:66471241:GC:G	acceptor_gain	1.0000
11:66471241:GCT:G	acceptor_gain	1.0000
11:66471241:GCTAC:G	acceptor_gain	1.0000
11:66473239:A:AG	acceptor_gain	1.0000
11:66473239:AG:A	acceptor_loss	1.0000
11:66473239:AGATT:A	acceptor_gain	1.0000
11:66473240:G:GA	acceptor_gain	1.0000
11:66473240:GA:G	acceptor_gain	1.0000
11:66473240:GATT:G	acceptor_gain	1.0000
11:66473240:GATTG:G	acceptor_gain	1.0000
11:66473431:TTGGA:T	donor_gain	1.0000
11:66473432:TGGA:T	donor_gain	1.0000
11:66473433:GGA:G	donor_gain	1.0000
11:66473433:GGAG:G	donor_gain	1.0000
11:66473434:GA:G	donor_gain	1.0000

AlphaMissense

3008 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:66472438:T:G	Y142D	1.000
11:66473244:G:C	G154R	1.000
11:66473245:G:A	G154D	1.000
11:66473245:G:T	G154V	1.000
11:66473247:C:A	R155S	1.000
11:66473248:G:C	R155P	1.000
11:66473269:A:T	D162V	1.000
11:66473335:T:A	I184N	1.000
11:66473340:C:A	R186S	1.000
11:66473340:C:G	R186G	1.000
11:66473352:C:A	R190S	1.000
11:66473353:G:C	R190P	1.000
11:66473404:G:A	G207D	1.000
11:66473406:T:A	F208I	1.000
11:66473406:T:C	F208L	1.000
11:66473406:T:G	F208V	1.000
11:66473407:T:C	F208S	1.000
11:66473407:T:G	F208C	1.000
11:66473408:C:A	F208L	1.000
11:66473408:C:G	F208L	1.000
11:66473425:T:A	I214N	1.000
11:66473425:T:C	I214T	1.000
11:66473425:T:G	I214S	1.000
11:66473427:T:C	F215L	1.000
11:66473429:C:A	F215L	1.000
11:66473429:C:G	F215L	1.000
11:66473434:G:A	G217E	1.000
11:66473752:T:A	W223R	1.000
11:66473752:T:C	W223R	1.000
11:66473780:G:A	G232E	1.000

dbSNP variants (sampled 300 via entrez): RS1000016908 (11:66466987 G>C), RS1000087031 (11:66467246 C>T), RS1000095733 (11:66467965 G>A), RS1000873232 (11:66468650 T>C), RS1001260299 (11:66468746 C>G,T), RS1001366635 (11:66474305 T>C), RS1002233999 (11:66467413 G>A,C,T), RS1002304584 (11:66467638 A>C,G), RS1002564110 (11:66474484 C>T), RS1002800879 (11:66476242 T>C), RS1003180821 (11:66475893 C>T), RS1003553778 (11:66477575 C>G), RS1003606802 (11:66470403 A>G), RS1004106600 (11:66474803 C>T), RS1004144697 (11:66469626 G>A)

Disease associations

OMIM: gene MIM:609827 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001241_12	Bipolar disorder	2.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression, increases methylation	3
Cisplatin	affects cotreatment, increases expression	2
Valproic Acid	affects expression, increases expression, increases methylation	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects response to substance, increases expression, affects cotreatment	1
pinostrobin	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Lead	affects expression	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Methotrexate	increases expression	1
Ozone	increases abundance, affects expression	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.